{'fraction_non_alphanumeric': 0.032302450530729915, 'fraction_numerical': 0.0314506617743415, 'mean_word_length': 5.129718875502008, 'pattern_counts': {'":': 0, '<': 3, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
HPV58 E7 Protein Expression Profile in Cervical Cancer and CIN with Immunohistochemistry

Background: The persistent infection of high-risk human papillomavirus (HR-HPV) is one of the most common causes of cervical cancer worldwide, and HPV type 58 (HPV58) is the third most common HPV type in eastern Asia. The E7 oncoprotein is constitutively expressed in HPV58-associated cervical cancer cells and plays a key role during tumorigenesis. This study aimed to assess the HPV58 E7 protein expression in the tissues of cervical cancer and cervical intraepithelial neoplasia (CIN). Methods: A total of 67 HPV58-positive cervical samples were collected, including 25 cervical cancer samples and 42 CIN samples. All the tissues were examined by HPV58 E7, p16INK4a and Ki67 immunohistochemistry (IHC). At last, we analyzed their association with clinical and pathological variables. Results: HPV58 E7 expression was detected in 96% of the HPV58 DNA-positive cervical cancer tissues and 85.7% of HPV58-positive CIN tissues. 65 samples of cervical cancer and CIN tissues had p16-positive staining, while 59 samples were Ki-67 positive. Conclusions: HPV58 E7 protein is highly expressed in both cervical cancer and CIN tissues. HPV58 E7 IHC could be sensitive and specific for evaluating HPV-driven cervical cancer and pre-cancerous lesions, in combination with p16 and Ki-67 IHC.


Introduction
Cervical cancer is one of the most common female genital cancers [1]. High-risk human papillomavirus (HR-HPV) is one major cause of cervical cancer, which accounts for over 500,000 new cancer cases and over 250,000 cancer deaths per year [2]. HPV type 16 (50%) and 18 (15%) are the most common subtypes worldwide. However, HPV type 58 (HPV58) plays a more prominent role in cervical cancer and pre-cancer (cervical intraepithelial neoplasia 1 (CIN1), CIN2, CIN3) in Asian countries. It is identified in 11.5% to 28% of cervical cancer patients in China [3].
HPVs are small, nonenveloped double-stranded DNA viruses that replicate their genomes in the nuclei of host cells (the keratinocytes). HR-HPV infection leads to the activation of viral gene expression, including the early genes E6 and E7 [4]. Their expression is important for cellular transformation process. The E7 oncoproteins degrade and inactivate the retinoblastoma tumor suppressor protein pRB, contributing to the malignant transformation of the host cells [5,6]. Specifically, the genomic and transcriptomic profiles of HPV58 in cervical neoplasia have been studied, and variants such as T20I and G63S substitutions at E7 of HPV58 were proposed to confer a significantly higher risk for cervical neoplasia [7,8]. However, the proteomes of HPV58, especially E7 oncoprotein, has not been well addressed. The detection of HPV58 E7 protein could be critical both in establishing the diagnosis of malignancy and assigning an HPV-related etiology to malignancy.

Ivyspring International Publisher
To date, a commercial antibody to HPV58 E7 for immunohistochemistry detection is still unavailable. We have produced and verified the specific polyclonal antibody against the HPV58 E7 protein [9]. In this study, we aimed to detect the HPV58 E7 protein expression using this antibody in the tissues of HPV58-positive cervical cancer and CIN with IHC. Meanwhile, we detected the Ki-67 and p16 expression, analyzed the correlations between HPV58 E7, p16, or Ki-67 expression levels and clinical and pathological variables. The E7 oncoproteins expression would be a potential marker for HPV58-related cervical cancer and CIN diagnosis and disease progression.

Study population
This study was performed according to the Declaration of Helsinki. The study protocol was approved by the Ethics Committee of Sir Run Run Shaw Hospital of Zhejiang University School of Medicine, China.
The following inclusion criteria were required to be included in the study: (1) histologically confirmed diagnosis of cervical cancer or CIN; (2) positive result of the HPV58 DNA test. Exclusion criteria included previous treatment for the cervical disease (including loop electrosurgical excision procedure (LEEP), cold-knife conization, cryotherapy, LASER therapy, or hysterectomy, prior chemotherapy or radiation treatment for cervical neoplasia, pregnancy, HIV infection, previous or co-existence of other malignant diseases. 25 cervical cancer patients and 42 CIN patients who were HPV58-positive detected by polymerase chain reaction (PCR) were included between January 2009 and August 2016 from Sir Run Run Shaw Hospital of Zhejiang University School of Medicine. Written informed consent was obtained from all the participants. Formalin-fixed and paraffin-embedded (FFPE) specimens from cervical cancer patients and CIN patients diagnosed according to the WHO classification of tumors of female reproductive organs by the Division of Pathology and were collected by the Departments of Obstetrics and Gynecology, Sir Run Run Shaw Hospital. Authors could access information that could identify individual participants during and after data collection.

Patient evaluation and disease monitoring
All patients' routine history had been taken, a physical examination, HPV test and cervical biopsy for morphological analysis. Morphologic diagnoses were based on consensus review by 2 subspecialty gynecologic pathologists. When morphology was equivocal, the diagnoses were adjudicated by a third gynecologic pathologist. LEEP or hysterectomy was performed and the removed tissues were transferred for histopathological examination. Besides, we collected the data on the degree of cell differentiation, tumor size and lymph node metastasis. Cervical carcinoma or CIN recurrences would be detectable by cervical biopsy during follow-up visits.

Statistical analysis
Categorical data analysis was conducted using the χ 2 test. Either the Student's t-test or Wilcoxon test was performed to determine the differences between groups. Spearman's correlation was used for the correlation analysis. Results were considered statistically significant at p < 0.05. All statistical analyses were done with SPSS22.0.

Immunohistochemical results
The results of immunohistochemical tests for HPV58 E7, p16 and Ki-67 are presented in Table 2 Table 2, the expression level of HPV58 E7, p16, and Ki-67 in cervical cancer tissues were higher than in CIN tissues. Representative photographs of positive color reactions are shown in Figure 1 and Figure 2.

Correlations between HPV58 E7, p16, or Ki-67 expression levels and clinical and pathological variables
Base on Table 2, we subdivided the staining results into 2 groups for further analyses: group 1 (weak and moderate staining), group 2 (strong staining). When we analyzed the age distribution of cervical cancer patients (Table 3), we found that HPV58 E7 expression level increased and Ki-67 expression decreased in older women (Table 4, p<0.05). Correlations of HPV58 E7, p16 and Ki-67 expression levels with clinical and histological variables in cervical cancer patients were demonstrated in Table 4. There were no significant differences in clinicopathological factors, including the degree of differentiation, the diameter of tumor lesions, staging of the tumor, lymph node metastasis, relapse, age of menarche, age of marriage, times of fetation and times of abortion between patients with low-moderate and strong expression level of HPV58 E7, p16, and Ki-67. However, p16 expression was associated with HPV58 E7 and Ki-67 expression ( Table 4, p<0.05). As revealed by Spearman's correlation, there's a positive correlation between p16 expression and HPV58 E7 (r=0.391, p=0.027) or Ki-67 expression (r=0.370, p=0.034). In CIN patients, there were no significant differences in clinicopathological factors between group 1 and group 2.

Discussion
In this study, we demonstrated the HPV58 E7 oncoprotein expression pattern in cervical cancer and CIN with immunohistochemistry. We determined the association of HPV58 E7 with other clinical and molecular parameters in cervical cancer samples.
Previous studies demonstrated that HR-HPV infection is associated with a broad spectrum of carcinogenesis in a variety of anatomic locations including the uterine cervix, vulva, anus, penis, and head and neck [11,12]. The HPV 16, 18 types are mostly associated with cervical carcinoma worldwide [13]. HPV-58 is a common subtype of HR-HPV, which accounts for a notable proportion of the cervical cancers in Asian countries. It has been identified in 11.5 to 28% of cervical carcinoma patients in China, 8% in Japan and 16% in Korea [14]. HPV16, 58, and 52 were the three most dominant HPV genotypes in cervical intraepithelial lesions in Shanghai [15]. In another study, they demonstrated HPV58 is the third most common HPV type in Eastern Asia overall [16].
DNA-based PCR is widely used in analyzing clinical specimens for the presence of HPV infection. However, the detection of DNA only indicates the presence of HPV and the expression of oncogenes are associated with progression to invasive cancer [17]. The E6 and E7 genes are the main oncogenes of HR-HPVs [18]. There should be an overexpression of the E7 gene from the integrated HPV genome. Some studies demonstrated the presence of E7-specific antibodies in sera in connection with increased risk of cervical cancer that may be detected up to 5 years prior to diagnosis [19]. However, the E7 antibodies were detected infrequently which might result from the low level of the HPV E7 antibodies in human sera. Another study showed seroprevalence of HPV18 E7 antibodies were significantly higher in HPV18 DNA-positive cervical cancer cases than controls. However, apparent limitations were observed. Firstly, cross-reactivity was evident among closely related HPV types. Secondly, one-third of cervical cancer cases showed no detectable E6 or E7 antibodies in sera among cases positive for HPV DNA [20]. Thus, we detected the E7 protein level in tissues of cervical cancer and CIN patients with the self-prepared polyclonal antibody [9]. The results revealed HPV58 E7 expressed in 96% of the HPV58 positive cervical cancer tissues examined, in 85.7% of HPV58 positive CIN tissues. The positive rate of E7 immunohistochemistry is relatively high in cervical cancer and CIN tissues. The method is worthy of clinical practice. The protein expression might be a useful marker for disease progression. However, there are still no type-specific commercial antibodies targeting HPV58 E7 oncoprotein in clinical application. In the current study, we evaluated the HPV58 E7 protein expression levels in cervical cancer and CIN samples by immunohistochemistry using a specific polyclonal antibody produced and verified by our research group [9]. We found that HPV58 E7 protein is highly expressed in cervical cancer and CIN samples by immunohistochemistry using this antibody, which provides evidence to support the reliability and potential of this antibody in clinical usage.   The HPV E7 protein in cooperation with E6 is essential for oncogenic cellular immortalization and transformation. E6 and E7 respectively induce the degradation of tumor suppressors p53 and retinoblastoma protein pRb [18,21]. In addition, HPV E7 proteins associate with the pocket proteins, p107 and p130, via the Leu-X-Cys-X-Glu (LXCXE) motif in their conserved region (CR) 2 domain [22]. The pocket proteins regulate G1/S transition by modulating the transcriptional activities of E2F transcription factors [23]. E2Fs also have effects on many other cellular processes relevant to tumorigenesis, including cellular differentiation, apoptosis, and genomic instability [24]. E7 proteins also interact with other proteins involved in cell proliferation, such as histone deacetylases [4], p21 and p27 cyclin-dependent kinase inhibitors [25] and components of the AP1 complex [26]. A report has indicated that HPV DNA replicates randomly or once per cell cycle in basal cells. The possible mechanism has been proposed, it may depend on the levels of the viral E1 replication protein and the cellular DNA replication protein components such as mini-chromosome-maintenance proteins (MCMs) [27]. A study showed HPV16-E7 transgenic keratinocytes with distinct cell surface markers attracted new antigen-presenting cell (APC) subsets to the epidermis. Transport of antigen to the draining lymph node by these APCs was markedly enhanced while antigen-processing was significantly impaired. They suggested E7 oncoprotein affected the phenotype and function of APCs and contributed to persisting infection with HPV [28]. HPV E7 may also induce the upregulation of RRM2 and promote ROS-ERK1/2-HIF-1α-VEGF-induced angiogenesis [29]. Furthermore, recent researches focused on immunotherapeutic approaches against E7-derived antigens in patients with cervical and oropharyngeal cancers [30,31]. A study found that E6/E7 mRNA expression level was higher in women with high grade squamous intraepithelial lesion (HSIL) and CIN grade 2 or higher [32]. The combination of HPV-positive DNA and E6 or E7 serology could predict overall survival in individuals with HPV infections [33]. We found that CIN patients showed a lower rate of HPV58 E7 IHC positive compared to malignancy patients. The detection of the HPV E7 protein allows the monitoring of the oncogenic activity of the virus. The Ki-67 protein is a proliferation marker that is detected in the cell nuclei during the G1, S and G2 phases of the cell cycle and in mitosis. It has been elucidated that the protein is essential for the proliferation process [34]. The p16 INK4a , a cyclin-dependent kinase (CDK) inhibitor, decelerates the cell cycle by inactivating the CDKs that phosphorylates the retinoblastoma protein (RB) [35]. The expression of E6 and E7 proteins leads to p16 upregulation through the RB-p16 pathway. Thus, p16 could be a useful biomarker to improve the diagnosis of cervical cancer and CIN in combining with conventional morphology [36,37]. The rates for p16 and Ki-67 expression correlate with the severity of cervical neoplasia [38][39][40]. In this study, p16 expression was found in 96% of the cancer group, and in 97.6% of the CIN group. The expression of the Ki-67 protein was demonstrated in 96% cancer cases, and in 83.3% CIN cases.
There were some limitations in our study. First, a smaller sample will give a result that may not be sufficiently powered to extrapolate the statistical difference. Second, as most of the cases were early-stage cervical cancers, survival analysis couldn't be conducted.

Conclusions
In conclusion, IHC for HPV58 E7 is a test with high specificity and sensitivity. The HPV58 E7 protein is highly expressed in cervical cancer and CIN patients. A novel marker for cervical cancer and CIN diagnosis and disease progression allows further implications for disease monitor. Larger studies are warranted to confirm our findings and to clarify the relationship between HPV58 E7 expression with clinical and pathological variables, which exhibits close correlations with other clinical and molecular parameters in cervical neoplasia, including p16 and Ki-67 expression. These findings provide evidence to support the reliability and potential of this antibody in clinical application [9].